Pathogenic Transthyretin Gene Mutations In Phenotypic Hypertrophic Cardiomyopathy: An Underrecognized Double Whammy

Varun Subashchandran,Anthony Kanelidis,Rachel Campagna,Gene Kim,Jeremy A. Slivnick
DOI: https://doi.org/10.1016/j.cardfail.2023.10.123
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Hypertrophic cardiomyopathy (HCM) is a common inherited cardiomyopathy with a prevalence of 1 in 500 patients. Genetic testing is generally recommended in order to differentiate between other cardiomyopathies with left ventricular (LV) hypertrophy such as hypertensive heart disease and cardiac amyloidosis (CA). Transthyretin cardiac amyloidosis (ATTR-CA) may occur either spontaneously or due to pathogenic gene mutations; in particular, the Val142Ile mutation may be present in as many as 3-4% of African American (AA) adults. Despite this relatively high prevalence of both HCM and ATTR-CA, the overlap between these two inherited cardiomyopathies is underrecognized. Accordingly, we present a case series of four patients with phenotypic HCM who were found to have Val142Ile mutations. Case Presentation Clinical and cardiac imaging characteristics of the four patients with Val142Ile mutations are presented in Figure 1A-B. Patient 1 was a 34 year-old African American (AA) male with a mid-ventricular HCM phenotype. His cardiac magnetic resonance (CMR) demonstrated extensive non-ischemic late gadolinium enhancement (LGE) burden involving the RV insertion points—a pattern typical of HCM. Rhythm monitoring revealed non-sustained ventricular tachycardia (NSVT) and Grade 0 uptake on a Tc-99 m PYP (Tc-PyP) scan. Patient 2 was a sixty-five AA female with basal septal HCM. Her CMR also showed typical HCM-pattern LGE involving the basal septum. They also had Grade 0 uptake on a Tc-PyP scan. Patient 3 was an eighteen-year-old AA male with apical HCM and no evidence of LGE on CMR; his genetic testing revealed both a Val142Ile mutation as well as a variant of undetermined significance in ALPK3. Lastly, patient 4 was a fifty-eight-year-old AA female with a basal septal phenotype. They had typical LGE for HCM with involvement of the septum and RV insertion points; his genetic testing revealed both Val142Ile and MYBPC3 mutations, the latter of which is strongly associated with HCM. Rhythm monitoring showed NSVT. Tc-PyP scans are currently pending for the latter two patients. Conclusions We described a case series of four AA patients with phenotypic HCM who were found to be asymptomatic carriers of Val142Ile mutations. The development of an ATTR-CA in a background of pre-existing HCM is potentially clinically devastating. Our study highlights the importance of systematic screening for ATTR mutations in phenotypic HCM in order to allow for timely initiation of life-prolonging TTR-targeted therapies. Additionally, given the potential overlap of these conditions, protocols are needed to define optimal screening and surveillance techniques for ATTR deposition in phenotypic HCM.
cardiac & cardiovascular systems
What problem does this paper attempt to address?